These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17006675)

  • 1. Interindividual variability of aminoglycoside pharmacokinetics in preterm neonates at birth.
    Allegaert K; Anderson BJ
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1011-2. PubMed ID: 17006675
    [No Abstract]   [Full Text] [Related]  

  • 2. Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics.
    Allegaert K; Sherwin CM
    Singapore Med J; 2010 Jan; 51(1):88-9. PubMed ID: 20200782
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical pharmacokinetics of aminoglycosides in the neonate: a review.
    Pacifici GM
    Eur J Clin Pharmacol; 2009 Apr; 65(4):419-27. PubMed ID: 19104791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.
    Mathews A; Bailie GR
    J Clin Pharm Ther; 1987 Oct; 12(5):273-91. PubMed ID: 3119606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Once-daily" versus "extended-interval" administration of aminoglycosides in neonates: need for standard terminology.
    Miller MM; Burton ME; Johnson PN; Miller JL
    Am J Health Syst Pharm; 2014 Dec; 71(24):2108-9. PubMed ID: 25465576
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of aminoglycosides in preterm neonates: a simple task?
    van den Anker J
    J Pediatr; 2009 Jun; 154(6):935. PubMed ID: 19446105
    [No Abstract]   [Full Text] [Related]  

  • 7. Limited predictability of amikacin clearance in extreme premature neonates at birth.
    Allegaert K; Anderson BJ; Cossey V; Holford NH
    Br J Clin Pharmacol; 2006 Jan; 61(1):39-48. PubMed ID: 16390350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age.
    Rengelshausen J; Beedgen B; Tsamouranis K; Mikus G; Walter-Sack I; Haefeli WE; Linderkamp O
    Eur J Clin Pharmacol; 2006 Sep; 62(9):773-7. PubMed ID: 16865390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside pharmacokinetics in neonates: the need to search for covariates of variability in addition to case descriptions.
    Allegaert K
    Acta Paediatr; 2009 Oct; 98(10):1546; author reply 1546-7. PubMed ID: 19659582
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring of aminoglycosides in neonates.
    Touw DJ; Westerman EM; Sprij AJ
    Clin Pharmacokinet; 2009; 48(2):71-88. PubMed ID: 19271781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal drug clearance in preterm neonates: relation to prenatal growth.
    Allegaert K; Anderson BJ; van den Anker JN; Vanhaesebrouck S; de Zegher F
    Ther Drug Monit; 2007 Jun; 29(3):284-91. PubMed ID: 17529884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of netilmicin in neonates].
    Piekarczyk A; Kaminska E; Taljanski W; Sosonowska K; Poszwinska B; Rutkowska M
    Med Wieku Rozwoj; 2003; 7(4 Pt 2):547-55. PubMed ID: 15213369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal delivery of aminoglycosides: amikacin transport and iontophoretic non-invasive monitoring.
    Nicoli S; Santi P
    J Control Release; 2006 Mar; 111(1-2):89-94. PubMed ID: 16413081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.
    Agence française de sécurité sanitaire des produits de santé
    Med Mal Infect; 2012 Jul; 42(7):301-8. PubMed ID: 22770656
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation.
    Bleyzac N; Varnier V; Labaune JM; Corvaisier S; Maire P; Jelliffe RW; Putet G; Aulagner G
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):499-504. PubMed ID: 11699615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants.
    Allegaert K; Debeer A; Cossey V; Rayyan M; Devlieger H
    Pediatr Crit Care Med; 2006 Mar; 7(2):143-6. PubMed ID: 16446602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.
    Sherwin CM; Svahn S; Van der Linden A; Broadbent RS; Medlicott NJ; Reith DM
    Eur J Clin Pharmacol; 2009 Jul; 65(7):705-13. PubMed ID: 19305985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized dosing of aminoglycosides in neonates: mission accomplished or work in progress?
    van den Anker JN; Allegaert K
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1159-60. PubMed ID: 19582439
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics.
    Olsson JM
    Pediatr Rev; 2007 Oct; 28(10):398. PubMed ID: 17908865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.